|Bid||13.80 x 1000|
|Ask||14.85 x 800|
|Day's range||14.35 - 14.80|
|52-week range||7.25 - 17.35|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||30.00|
The New York-based company said it had a loss of 46 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a ...
Jim Cramer rattles off his take on callers' favorite stocks, including an oil play subject to an investor-led sea change.
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that updated data for ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, has been selected for presentation at the upcoming third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018, to be held February 1 - 3, 2018, in San Diego, California. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, "We look forward to presenting updated data from our Phase 2 study of ublituximab in relapsing multiple sclerosis at the ACTRIMS conference in February.
On a per-share basis, the New York-based company said it had a loss of 48 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...